Search results for "Anas"

showing 10 items of 2757 documents

Identification and analysis of security risks of the Information system and website

2021

2ANOTĀCIJA Darba mērķis ir izanalizēt izplatītākos drošības riskus tīmekļvietnēm un informācijas sistēmām, nosakot tos, veikt ielaušanas testēšanu uz noteikto tīmekļvietni. Tēma ir īpaši aktuāla, jo mūsdienu pasaulē ar tehnoloģiju attīstību un arī Covid-19 laikā vie tnes arvien vairāk sāk sniegt tiešsaistes pakalpojumus. Tīmekļvietnes apstrādā un glabā lietotāju sensitīvo informāciju un nevar būt 100% droša,līdz ar ko krāpnieku interese pieaug. Darb ā ir izanalizētamūsdienas drošības situācija,statistika par tīmekļvietnēm, kā arī izmantojot OWASP datus ir noskaidroti visizplatītākie drošības riski un drošības līdzekļi pret tiem. Izmantojot informāciju par drošības riskiem,darba ietvaros ir …

OWASPDatorzinātnedrošības riskiKali Linuxtīmekļvietneielaušanas testēšana
researchProduct

El héroe mítico como personaje secundario en los prólogos de las tragedias de Séneca

2015

Además de la función introductoria e informativa, los prólogos de las tragedias de Séneca cumplen una función en su configuración, para que los destinatarios de las mismas sean introducidos en el drama y en el ‘pazos’ de los personajes. Para ello el autor diseña el prólogo como un bosquejo de tragedia en el que los elementos que constituyen el drama clásico – conflicto y personajes principales y secundarios – son utilizados con independencia, mayor o menor, de la historia principal. La variedad de estas piezas rebela el deseo experimentador del autor Besides the introductory and informative function, prologues of Seneca’s tragedies fulfill a function in setting, so that recipients of these …

OedipusUNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASAgamemnonThyestesMedeaSéneca trágico:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]TroyanasHercules furens
researchProduct

Incidencia de las clases urbanas de la Ciudad de Valencia en la distribución de la renta inmobiliaria del área central del Pais Valenciano a finales …

1990

LA RECOPILACION DE EXTRACTOS DE LOS PADRONES DE RIQUEZA LOCALES QUE SE REALIZO EN 1805 PARA REPARTIR UN PRESTAMO EXTRAORDINARIO, HA PERMITIDO DISPONER DE LA DISTRIBUCION DE LA RENTA INMOBILIARIA EN 55 MUNICIPIOS DE LAS COMARCAS CENTRALES DEL PAIS VALENCIANO. EL ANALISIS SE HA CENTRADO EN LA DISTRIBUCION DE LA RENTA EN FUNCION DE LA RESIDENCIA DE LOS DECLARANTES, COMPROBANDO LA PRESENCIA HABITUAL DE DECLARANTES FORASTEROS Y EL PAPEL DOMINANTE QUE JUGABAN ENTRE ESTOS LOS RESIDENTES DE LA CIUDAD DE VALENCIA. DE AHI QUE SE HAYA PROFUNDIZADO EN SU ESTUDIO CON EL FIN DE AVERIGUAR LA COMPOSICION SOCIAL DE ESTE COLECTIVO. FINALMENTE, SE HA ANALIZADO LA EXISTENCIA DE UNA BURGUESIA LOCAL EN LOS MUNIC…

Oligarquía urbanaPropiedad agrariaUNESCO::HISTORIA::Historia por épocas::Historia antiguaPropietariosClases urbanasDistribución de la rentaOligarquía ruralAntiguo RégimenBienes inmuebles:HISTORIA::Historia por épocas::Historia antigua [UNESCO]Historia Moderna
researchProduct

Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity

2012

Membrane microvesicle shedding is an active process and occurs in viable cells with no signs of apoptosis or necrosis. We report here that microvesicles shed by oligodendroglioma cells contain an ‘aggrecanase’ activity, cleaving aggrecan at sites previously identified as targets for adamalysin metalloproteinases with disintegrin and thrombospondin domains (ADAMTSs). Degradation was inhibited by EDTA, the metalloproteinase inhibitor GM6001 and by tissue inhibitor of metalloproteinases (TIMP)-3, but not by TIMP-1 or TIMP-2. This inhibitor profile indicates that the shed microvesicles contain aggrecanolytic ADAMTS(s) or related TIMP-3-sensitive metalloproteinase(s). The oligodendroglioma cells…

OligodendrogliomaMembrane vesicleRA rheumatoid arthritisADAMTSMatrix metalloproteinaseCell Physiological PhenomenaAdamalysin03 medical and health sciences0302 clinical medicineSettore BIO/10 - BiochimicaEndopeptidasesHumansAggrecansADAM adamalysinADAMTS a disintegrin and metalloproteinase with thrombospondin motifsMolecular BiologyMetalloproteinase030304 developmental biologyAggrecanaseTissue Inhibitor of Metalloproteinase-3MEF mouse embryonic fibroblasts0303 health sciencesMetalloproteinaseChemistryBrief ReportMVs microvesiclesADAMTSMicrovesicleCytoplasmic VesiclesDipeptidesFibroblastsMolecular biologyRecombinant ProteinsMicrovesiclesECM extracellular matrixMembrane vesiclesCell biologyEnzyme ActivationMMP matrix metalloproteinaseADAM ProteinsADAMTS4030220 oncology & carcinogenesisProteolysisADAMTS5 ProteinRheumatic FeverTIMP tissue inhibitor of metalloproteinaseAggrecan
researchProduct

The Assessment of Risk Factors for Long-term Survival Outcome in ypN0 Patients With Rectal Cancer After Neoadjuvant Therapy and Radical Anterior Rese…

2021

Abstract Background The main negative prognostic factors in patients with rectal cancer after radical treatment include regional lymph node involvement, lymphovascular invasion, and perineural invasion. However, some patients still develop cancer recurrence despite the absence of the above risk factors. The aim of the study was to assess clinicopathological factors influencing long-term oncologic outcomes in ypN0M0 rectal cancer patients after neoadjuvant therapy and radical anterior resection. Methods A retrospective survival analysis was performed on a group of 195 patients. We assessed clinicopathological factors which included tumor regression grade, number of lymph nodes in the specime…

OncologyAnterior rectal resectionmedicine.medical_specialtyRD1-811Lymphovascular invasionColorectal cancermedicine.medical_treatmentPerineural invasion030230 surgeryDisease-Free Survival03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineLymph node yieldHumansLymph nodeNeoadjuvant therapySurvival analysisRC254-282Neoplasm StagingRetrospective StudiesTumor Regression GradeUnivariate analysisbusiness.industryLate anastomotic leakRectal NeoplasmsResearchNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisNeoadjuvant Therapymedicine.anatomical_structureOncologyStage migration030220 oncology & carcinogenesisSurgeryNeoplasm Recurrence LocalbusinessCharlson comorbidity index
researchProduct

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

2013

Background: ER þ/HER2 � breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy. Methods: A total of 1702 postmenopausal ER þ/HER2 � breast cancer patients from two adjuvant phase III trials (ABCSG6, ABCSG8) treated with 5 years of endocrine therapy participated in this study. The multigene test EndoPredict (EP) and the EPclin score (which combines EP with tumour size and nodal status) were predefined in independent training cohorts. All patients were retrospectively assigned to risk categories based on gene expression and on clinical parameters. The primary…

OncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalReceptor ErbB-2AnastrozoleBreast NeoplasmsCell Growth ProcessesAnastrozoleBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsNitrilesClinical endpointHumansMedicineNeoplasm MetastasisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective Studiesendocrine therapybusiness.industryProportional hazards modelGene Expression ProfilingCell DifferentiationRetrospective cohort studyTriazolesPrognosismedicine.diseaseSurgeryClinical triallate relapseTamoxifenTreatment OutcomeEditorialClinical Trials Phase III as TopicReceptors EstrogenOncologyClinical StudyHormonal therapyFemaleNeoplasm Recurrence LocalEndoPredictbusinessTamoxifenSignal Transductionmedicine.drugBritish Journal of Cancer
researchProduct

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuva…

2009

Abstract Background Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC. Methods We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4th month by World Health Organization (WHO) criteria. Three polymorphisms of CYP19A1, one in exon 7 (rs700519) and two in…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAnastrozoleAntineoplastic AgentsBreast Neoplasmslcsh:RC254-282AromataseBreast cancerSurgical oncologyInternal medicineNitrilesGeneticsmedicineHumansAromatase3' Untranslated RegionsNeoadjuvant therapyAgedAged 80 and overPolymorphism GeneticAromatase inhibitorbiologybusiness.industryLetrozoleMiddle AgedTriazoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryNeoadjuvant TherapyPostmenopauseTreatment OutcomeEndocrinologyOncologyLetrozoleDisease Progressionbiology.proteinFemalebusinessTamoxifenResearch Articlemedicine.drugBMC Cancer
researchProduct

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a r…

2018

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely remov…

OncologyReceptor ErbB-2Settore MED/06 - Oncologia Medicaletrozolelaw.inventionAdjuvant anastrozolechemistry.chemical_compound0302 clinical medicineRandomized controlled trialExemestanelawAdjuvant anastrozole; exemestane; letrozole; tamoxifen; breast cancerAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicinetamoxifenAromatase InhibitorsLetrozoleHazard ratioMiddle AgedReceptors EstrogenTolerabilityOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleReceptors ProgesteroneBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtySocio-culturaleAnastrozoleBreast NeoplasmsAnastrozoleDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineAromatase InhibitorHumansAgedAntineoplastic Combined Chemotherapy ProtocolAndrostadienebusiness.industrymedicine.diseaseAndrostadieneschemistrybusinessexemestaneTamoxifen
researchProduct

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

2012

Background In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed. Patients and methods We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPc…

Oncologymedicine.medical_specialtyEndoPredict geneAntineoplastic Agents HormonalReceptor ErbB-2Populationadjuvant treatmentBreast NeoplasmsKaplan-Meier EstimateAnastrozoleRisk AssessmentDisease-Free SurvivalBreast cancerInternal medicineBreast CancerexpressionAntineoplastic Combined Chemotherapy ProtocolsNitrilesmedicineHumanseducationSurvival analysisRetrospective Studieseducation.field_of_studybusiness.industryendocrine therapyAbsolute risk reductionRetrospective cohort studyHematologyOriginal ArticlesMiddle AgedTriazolesmedicine.diseasePrognosisChemotherapy regimenSurgeryTamoxifenTreatment OutcomeOncologyReceptors EstrogenChemotherapy AdjuvantPractice Guidelines as TopicFemaleBreast diseasebusinessRisk assessmentAnnals of Oncology
researchProduct

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patient…

2020

<b><i>Background:</i></b> Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. <b><i>Methods:</i></b> For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). <b><i>Res…

Oncologymedicine.medical_specialtymedicine.drug_classPopulationAnastrozoleNOInternal medicineFulvestrant · First-line setting · Hormone receptor positive Advanced breast cancermedicineAdjuvant therapyProgression-free survivaleducationFulvestrantFirst-Line settingeducation.field_of_studyHormone receptor positiveAromatase inhibitorFulvestrantEVAbusiness.industrytrialsCancerEndocrine TherapyGIM-13medicine.diseaseEndocrine Therapy HR+/HER2– Advanced Breast Cancer High-Dose Fulvestrant First-Line setting EVA GIM-13 AMBRA trialsAdvanced breast cancer; First-line setting; Fulvestrant; Hormone receptor positiveOncologyHR+/HER2–Advanced Breast CancerSurgeryAMBRAbusinessHigh-DoseTamoxifenResearch Articlemedicine.drug
researchProduct